SupremeToday Landscape Ad
Back
Next
Judicial Analysis Court Copy Headnote Facts Arguments Court observation
Listen Audio Icon Pause Audio Icon
judgment-img

2025 Supreme(Del) 297

IN THE HIGH COURT OF DELHI AT NEW DELHI 
AMIT BANSAL, J.
 
Macleods Pharmaceuticals Ltd - Petitioner 
Versus 
The Controller Of Patents & Anr. - Respondents
I.A. 7635 of 2024 and I.A. 46685 of 2024 IN C.O. (COMM. IPD-PAT) 38 of 2022 
Decided on : 15-01-2025
 

Advocates Appeared:
For the Petitioner:Mr. G. Nataraj and Mr. Rahul Bhujbal and Mr. Yash Raj, Advocates
For the Respondent:Mr. Sandeep Sethi, Sr. Adv. with Dr. Sanjay Kumar, Ms. Arpita Sawhney, Ms. Meenal Khurana, Ms. Pallavi Kiran, Mr. Arun Kumar Jana, Mr. Priyansh Sharma, Ms. Pratiksha Varshney, Mr. Sumer Seth and Ms. Riya Kumar, Advocates

A revocation petition under Section 64 of the Patents Act can be maintained even after the patent's expiry, as the petitioner qualifies as a 'person interested' and the cause of action for damages survives.

Headnote:(A) Patents Act, 1970 - Sections 64(1), 107, 151, and 2(1)(t) - Revocation petition - Maintainability of revocation petition after patent expiry - The court held that a revocation petition can be filed even after the patent's expiry, as the petitioner qualifies as a 'person interested' and the cause of action for damages survives. (Paras 30-38)

(B) Distinction between revocation and invalidity - The court clarified that the scope of a revocation petition under Section 64 is different from a defense of invalidity under Section 107, emphasizing that a revocation petition can be filed independently of ongoing infringement suits. (Paras 16-29)

Facts of the case:
The petitioner filed a revocation petition against a patent for an anti-diabetic drug, which was granted in 2022, just before launching a generic version. The respondent filed an infringement suit shortly after. The patent expired in 2023.

Findings of Court:
The court found that the revocation petition is maintainable despite the patent's expiry, as the petitioner is a 'person interested' and the cause of action for damages persists.

Issues: The main issues were the maintainability of the revocation petition after the patent's expiry and the distinction between a revocation petition and a defense of invalidity in an infringement suit.

Ratio Decidendi: The court ruled that the revocation petition can be filed independently and remains valid even after the patent's expiry, as the petitioner has a legitimate interest.

Result: Both applications for dismissal were dismissed.

JUDGMENT :

AMIT BANSAL, J.

I.A. 7635/2024 (under Section 151 of CPC) I.A. 46685/2024 (under Section 151 of CPC)

1. The captioned applications have been filed by the respondent no.2 seeking dismissal of the present petition.

2. The following issues arise for adjudication in the two applications:

(i) Whether a revocation petition can be held to be not maintainable if the petitioner has filed a written statement, taking a defence of invalidity of the suit patent under Section 107 of the Patents Act, in an infringement suit filed by the patentee.

(ii) Whether a revocation petition can be filed or sustained (if already filed) after the expiry of the term of the patent.

PREFATORY  FACTS

3. The petitioner, Macleods Pharmaceuticals Ltd., is engaged in manufacturing and marketing of diverse pharmaceutical products including anti-diabetic drugs.

4. The respondent no. 2, Boehringer Ingelheim Pharma GmbH & Co. KG, is a company organized and existing under the laws of Germany. It is engaged in the business of developing, manufacturing and marketing pharmaceuticals worldwide including India.

5. The present revocation petition was filed by the petitioner under Section 64(1) of the Patents Act, 1970 (hereinafter the ‘Patents Act’) seeking revocation of Indian Patent IN 243301 registered in the name of the respondent no. 2 in respect of a medicinal product called ‘LINAGLIPTIN’ an anti-diabetic product (hereinafter ‘the subject patent’). The subject patent was granted in favour of the respondent no. 2 on 5th October, 2022 with the priority date of 21st August, 2002.

6. The present petition was filed on 17th  February, 2022 just before the intended date for the commercial launch of the petitioner’s generic ‘LINAGLIPTIN’ product, i.e. 22nd  February, 2022.

7. Subsequently, on 19th February, 2022, the respondent no.2 filed an infringement suit against the petitioner herein before the High Court of Himachal Pradesh (COMS 3/2022), alleging infringement of the subject patent (hereinafter the ‘Himachal Suit’).

8. The term of the subject patent expired on 18th August, 2023.

9. On 4th May, 2022, the respondent no. 2 filed an application being I.A. 5611/2022 under Order VII Rule 11 of the Code of Civil Procedure, 1908 (‘CPC’) seeking dismissal of the present revocation petition on the ground that it was filed twelve years after the grant of the subject patent. This Court vide oral judgement dated 27th July, 2022 dismissed the said application on the ground that there is no prescribed time limit to file a revocation petition.

10. The respondent no. 2 had also filed an application being I.A. 13077/2023 seeking transfer of the present revocation petition to the High Court of Himachal Pradesh, to be consolidated with the Himachal Suit. However, the said application was also dismissed by the Predecessor Bench vide order dated 20th July, 2023.

11. On 2nd April, 2024, I.A. 7635/2024 has been filed on behalf of the respondent no. 2 stating that since the subject patent has expired on 18th August, 2023, nothing survives in the present revocation petition and, therefore, the same should be dismissed.

12. Thereafter, on 8th May, 2024, the petitioner filed a transfer petition bearing no. T.P.(C) 1412/2024 before the Supreme Court seeking transfer of the Himachal Suit to this Court, which is pending before the Supreme Court.

13. Subsequently, on 25th  November, 2024, I.A. 46685/2024 has been filed on behalf of the respondent no. 2 seeking dismissal of the present revocation petition on the ground that the petitioner has filed a written statement seeking invalidity of the subject patent in the Himachal Suit.

SUBMISSIONS ON BEHALF OF THE  RESPONDENT  NO. 2

14. Mr. Sandeep Sethi, Senior Counsel appearing on behalf of the respondent no.2 has made the following submissions:

14.1. The defence of invalidity under Section 107 of the Patents Act has already been taken by the petitioner in its written statement filed in the Himachal Suit. The prayers sought by the petitioner in the presen

Click Here to Read the rest of this document
1
2
3
4
5
6
7
8
9
10
11
Judicial Analysis

AI

SupremeToday Portrait Ad
supreme today icon
logo-black

An indispensable Tool for Legal Professionals, Endorsed by Various High Court and Judicial Officers

Please visit our Training & Support
Center or Contact Us for assistance

qr

Scan Me!

India’s Legal research and Law Firm App, Download now!

For Daily Legal Updates, Join us on :

whatsapp-icon Back to top